Publications by authors named "Michael M Shi"

Claim this Profile
S
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).
Jianming Xu, Lin Shen, Jie Li, Zhiwei Zhou, Chunmei Bai, Michael M Shi

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.
Xin Zhao, Jing Sun, Zhihua Zhang, Miao Chen, Tiejun Gong, Michael M Shi

Lancet Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.
Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang, Ruibin Huang, Michael M Shi

Lancet Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR, HER2 breast cancer that had progressed during or after prior endocrine therapy.
Antonino Musolino, Mario Campone, Patrick Neven, Neelima Denduluri, Carlos H Barrios, Michael M Shi

Breast Cancer Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Robert J Motzer, Camillo Porta, Nicholas J Vogelzang, Cora N Sternberg, Cezary Szczylik, Michael M Shi

Lancet Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Gottfried E Konecny, Teodora Kolarova, Neil A O'Brien, Boris Winterhoff, Guorong Yang, Michael M Shi

Mol Cancer Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
Niantao Deng, Liang Kee Goh, Hannah Wang, Kakoli Das, Jiong Tao, Michael M Shi

Gut· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
Hung Huynh, Pierce Kah Hoe Chow, Wai Ming Tai, Su Pin Choo, Alexander Yaw Fui Chung, Michael Ming Shi

J Hepatol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kevin B Kim, Jason Chesney, Douglas Robinson, Humphrey Gardner, Michael M Shi

Clin Cancer Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
Michael I Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C Gatter, Tanja Trarbach, Michael M Shi

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Toyoaki Hida, Motohiro Tamiya, Makoto Nishio, Nobuyuki Yamamoto, Tomonori Hirashima, Takeshi Horai, Michael M Shi, Ken Kobayashi, Yoshitsugu Horio

Cancer Sci· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF polymorphisms and risk of melanocytic neoplasia.
Michael R James, Richard B Roth, Michael M Shi, Stefan Kammerer, Matthew R Nelson

J Invest Dermatol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large-scale validation of single nucleotide polymorphisms in gene regions.
Matthew R Nelson, George Marnellos, Stefan Kammerer, Carolyn R Hoyal, Michael M Shi

Genome Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism.
Stefan Kammerer, Lora L Burns-Hamuro, Yuliang Ma, Sara C Hamon, Jaume M Canaves, Michael M Shi

Proc Natl Acad Sci U S A· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes.
Michael M Shi

Am J Pharmacogenomics· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostics meets therapeutics: the impact of pharmacogenetics.
Michael M Shi

Drug Discov Today· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis